Three Antigen Hepatitis B Vaccine Found Effective

In COVID-19, Latest News by Precision Vaccinations

Massachusetts-based VBI Vaccines Inc. recently announced that Phase 3 study results of its prophylactic 3-antigen hepatitis B (HBV) vaccine candidate were published in The JAMA Network Open.
The CONSTANT study was designed to demonstrate manufacturing equivalence of three lots of VBI’s HBV vaccine candidate and evaluate the immunogenicity of VBI’s 3-antigen HBV vaccine candidate compared to a single-antigen HBV vaccine, Engerix-B®, after two and three doses, and safety and reactogenicity.

Read More